Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Revenue (2021 - 2025)

Oncology Institute (TOI) has disclosed Revenue for 5 consecutive years, with $136.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue rose 36.7% year-over-year to $136.6 million, compared with a TTM value of $461.0 million through Sep 2025, up 21.67%, and an annual FY2024 reading of $393.4 million, up 21.33% over the prior year.
  • Revenue was $136.6 million for Q3 2025 at Oncology Institute, up from $119.8 million in the prior quarter.
  • Across five years, Revenue topped out at $136.6 million in Q3 2025 and bottomed at $48.6 million in Q1 2021.
  • Average Revenue over 5 years is $80.7 million, with a median of $80.2 million recorded in 2023.
  • The sharpest move saw Revenue surged 38.13% in 2023, then rose 10.29% in 2025.
  • Year by year, Revenue stood at $52.3 million in 2021, then surged by 36.56% to $71.4 million in 2022, then grew by 20.11% to $85.8 million in 2023, then grew by 16.88% to $100.3 million in 2024, then soared by 36.2% to $136.6 million in 2025.
  • Business Quant data shows Revenue for TOI at $136.6 million in Q3 2025, $119.8 million in Q2 2025, and $104.4 million in Q1 2025.